Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Nanoscience
  4. Volume 21, Issue 4
  5. Article
Volume 21, Issue 4
  • ISSN: 1573-4137
  • E-ISSN: 1875-6786

Abstract

Psoriasis is a non-contagious, continuing, auto-immune disease that mostly affects the skin, and about 2%-3% of the world's population suffers from it. In this review article, the primary focus is on the strategies involved in conventional therapies and the latest advances that have been recorded in metallic nano, polymer-based, and lipid-based formulations in the spectrum of anti-psoriatic drugs. Liposomes, ethosomes, solid lipid nanoparticles, micelles, and dendrimers are only some of the nanocarrier systems that have been extensively researched in relation to their potential use in nano formulations. This study incorporates patent applications that illustrate the nanoparticle's function in treating psoriasis. Hence, on the basis of an extensive literature survey, it is concluded that nano-formulations are a promising medium to treat a disease like psoriasis as they offer enhanced penetration, target-specific delivery, and improved efficacy. When applied to the study of biological systems and the development of novel medical technologies, nanobiotechnology offers potentially promising possibilities for the efficient use of nanoscale materials and processes. In this approach, nanotechnology and biotechnology are combined in order to develop nanoscale devices, materials, and systems that can be used for the diagnosis, treatment, and prevention of psoriasis. The future of the therapeutic effect of antipsoriatic drugs is dependent on both the benefits they have the ability to bring and the progress being made in the mass production of these carriers. Researching novel carrier systems or combination therapies is essential, but so is working to scale up existing technologies so they may be commercialised and used to benefit society at large.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnano/10.2174/0115734137301584240722054651
2024-08-23
2025-04-24

  • From This Site

    /content/journals/cnano/10.2174/0115734137301584240722054651
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PradhanM. AlexanderA. SinghM.R. SinghD. SarafS. SarafS. Ajazuddin, Understanding the prospective of nano-formulations towards the treatment of psoriasis.Biomed. Pharmacother.201810744746310.1016/j.biopha.2018.07.15630103117
     [Google Scholar]
  2. RachakondaT.D. SchuppC.W. ArmstrongA.W. Psoriasis prevalence among adults in the United States.J. Am. Acad. Dermatol.201470351251610.1016/j.jaad.2013.11.01324388724
     [Google Scholar]
  3. OgawaK. OkadaY. The current landscape of psoriasis genetics in 2020.J. Dermatol. Sci.20209912810.1016/j.jdermsci.2020.05.00832536600
     [Google Scholar]
  4. KaushikS.B. LebwohlM.G. Psoriasis: Which therapy for which patient.J. Am. Acad. Dermatol.2019801435310.1016/j.jaad.2018.06.05630017706
     [Google Scholar]
  5. WollinaU. TirantM. VojvodicA. LottiT. Treatment of psoriasis: Novel approaches to topical delivery.Open Access Maced. J. Med. Sci.20197183018302510.3889/oamjms.2019.41431850114
     [Google Scholar]
  6. PatraJ.K. DasG. FracetoL.F. CamposE.V.R. Nano based drug delivery systems: recent developments and future prospects.J Nanobiotechnology20181617110.1186/s12951‑018‑0392‑8
     [Google Scholar]
  7. ZhouS. LuL. LiuD. WangJ. SakiyamaH. MuddassirM. Nezamzadeh-EjhiehA. LiuJ. Series of highly stable Cd( ii )-based MOFs as sensitive and selective sensors for detection of nitrofuran antibiotic.CrystEngComm202123468043805210.1039/D1CE01264A
     [Google Scholar]
  8. KimW.B. JeromeD. YeungJ. Diagnosis and management of psoriasis.Can. Fam. Physician.201763278
     [Google Scholar]
  9. RendonA. SchäkelK. Psoriasis pathogenesis and treatment.Int. J. Mol. Sci.2019206147510.3390/ijms2006147530909615
     [Google Scholar]
  10. RaharjaA. MahilS.K. BarkerJ.N. Psoriasis: a brief overview.Clin Med202121317017310.7861/clinmed.2021‑0257
     [Google Scholar]
  11. TorsekarR. GautamM. Topical therapies in psoriasis.Indian Dermatol. Online J.20178423524510.4103/2229‑5178.20962228761838
     [Google Scholar]
  12. CoondooA. PhiskeM. VermaS. LahiriK. Side-effects of topical steroids: A long overdue revisit.Indian Dermatol. Online J.20145441642510.4103/2229‑5178.14248325396122
     [Google Scholar]
  13. IbbotsonS.H. A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy.Front. Med.2018518410.3389/fmed.2018.0018430013973
     [Google Scholar]
  14. GisondiP. Del GiglioM. GirolomoniG. Treatment approaches to moderate to severe psoriasis.Int. J. Mol. Sci.20171811242710.3390/ijms1811242729144382
     [Google Scholar]
  15. LowesM.A. Suárez-FariñasM. KruegerJ.G. Immunology of Psoriasis.Annu. Rev. Immunol.201432122725510.1146/annurev‑immunol‑032713‑12022524655295
     [Google Scholar]
  16. How Biologics Are Used for Psoriasis Treatment.Available from: https://www.webmd.com/skin-problems-and-treatments/psoriasis/psoriasis-biologics (accessed October 20, 2021).
  17. JeonC. SekhonS. YanD. AfifiL. NakamuraM. BhutaniT. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Hum. Vaccin. Immunother.201713102247225910.1080/21645515.2017.135649828825875
     [Google Scholar]
  18. SchopfR.E. AustH. KnopJ. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab.J. Am. Acad. Dermatol.200246688689110.1067/mjd.2002.12047212063486
     [Google Scholar]
  19. Treating Moderate to Severe Psoriasis.Available from: https://www.webmd.com/skin-problems-and-treatments/psoriasis/severe-psoriasis (accessed October 16, 2021).
  20. VentolaC.L. Progress in Nanomedicine: Approved and investigational nanodrugs.Pharm. Ther.201742742
     [Google Scholar]
  21. MendonçaC.O. BurdenA.D. Current concepts in psoriasis and its treatment.Pharmacol. Ther.200399213314710.1016/S0163‑7258(03)00041‑X12888109
     [Google Scholar]
  22. RoelofzenJ.H.J. AbenK.K.H. OldenhofU.T.H. CoenraadsP.J. AlkemadeH.A. van de KerkhofP.C.M. van der ValkP.G.M. KiemeneyL.A.L.M. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema.J. Invest. Dermatol.2010130495396110.1038/jid.2009.38920016499
     [Google Scholar]
  23. Clay CatherJ. AbramovitsW. MenterA. Cyclosporine and tacrolimus in dermatology.Dermatol. Clin.2001191119137, ix10.1016/S0733‑8635(05)70234‑511155577
     [Google Scholar]
  24. GuptaA.K. ChowM. Pimecrolimus: A review.J. Eur. Acad. Dermatol. Venereol.200317549350310.1046/j.1468‑3083.2003.00692.x12941081
     [Google Scholar]
  25. KragballeK. Treatment of psoriasis with calcipotriol and other vitamin D analogues.J. Am. Acad. Dermatol.19922761001100810.1016/0190‑9622(92)70302‑V1479078
     [Google Scholar]
  26. Psoriasis Treatments: How To Get Rid of Psoriasis.Available from: https://www.webmd.com/skin-problems-and-treatments/psoriasis/understanding-psoriasis-treatment (accessed October 16, 2021).
  27. FluhrJ.W. CavallottiC. BerardescaE. Emollients, moisturizers, and keratolytic agents in psoriasis.Clin Dermatol200826438038610.1016/j.clindermatol.2008.01.015
     [Google Scholar]
  28. Tazorac: Uses, side effects, how to use, and more.Avaialble from: https://www.medicalnewstoday.com/articles/tazorac
  29. SpulsP I. RozenblitM. LebwohlM. Retrospective study of the efficacy of narrowband UVB and acitretin.J. Dermatolog. Treat.2003141720
     [Google Scholar]
  30. MaccaroniE. GiovenzanaG.B. PalmisanoG. BottaD. VolanteP. MasciocchiN. Structures from powders: Diflorasone diacetate.Steroids200974110211110.1016/j.steroids.2008.09.01419013475
     [Google Scholar]
  31. PauporteM. MaibachH. LoweN. PuglieseM. FriedmanD.J. MendelsohnH. CargillI. RamirezR. Fluocinolone acetonide topical oil for scalp psoriasis.J. Dermatolog. Treat.200915636036410.1080/09546630410023566
     [Google Scholar]
  32. PappK.A. BlauveltA. BukhaloM. GooderhamM. KruegerJ.G. LacourJ-P. MenterA. PhilippS. SofenH. TyringS. BernerB.R. VisvanathanS. PamulapatiC. BennettN. FlackM. SchollP. PadulaS.J. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.N. Engl. J. Med.2017376161551156010.1056/NEJMoa1607017
     [Google Scholar]
  33. NaldiL. YawalkarN. KaszubaA. OrtonneJ.P. MorelliP. RovatiS. MautoneG. Efficacy and safety of the betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis.Am J Clin Dermatol20121219120110.2165/11539780‑000000000‑00000
     [Google Scholar]
  34. Del RossoJ. FriedlanderS.F. Corticosteroids: Options in the era of steroid-sparing therapy.J. Am. Acad. Dermatol.20055311S50S5810.1016/j.jaad.2005.04.03015968264
     [Google Scholar]
  35. GuptaA.K. ChowM. Prednicarbate (Dermatop®): Profile of a corticosteroid.J. Cutan. Med. Surg.20168424424710.1177/120347540400800408
     [Google Scholar]
  36. R SullivanJ. A PredaV. Treatments for severe psoriasis.Aust. Prescr.2009321141810.18773/austprescr.2009.006
     [Google Scholar]
  37. SainiR. TutroneW. WeinbergJ. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.Curr. Pharm. Des.200511227328010.2174/138161205338223215638763
     [Google Scholar]
  38. LeeA. ScottL.J. Certolizumab pegol: A review in moderate to severe plaque psoriasis.BioDrugs202034223524410.1007/s40259‑020‑00416‑z32207094
     [Google Scholar]
  39. SubediS. GongY. ChenY. ShiY. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.Drug Des. Devel. Ther.2019132491250210.2147/DDDT.S20014731413544
     [Google Scholar]
  40. AbroukM. NakamuraM. LeeK. Secukinumab in the treatment of psoriasis and psoriatic arthritis: A review of the literature.Skin Therapy Lett.20172216Available from: https://pubmed.ncbi.nlm.nih.gov/28732152/
    [Google Scholar]
  41. CraigS. WarrenR.B. Ixekizumab for the treatment of psoriasis: up-to-date.Expert Opin. Biol. Ther.202020654955710.1080/14712598.2020.172973632050819
     [Google Scholar]
  42. FoulkesA.C. WarrenR.B. Brodalumab in psoriasis: evidence to date and clinical potential.Drugs Context2019811110.7573/dic.212570
     [Google Scholar]
  43. MegnaM. BalatoA. RaimondoA. BalatoN. Guselkumab for the treatment of psoriasis.Expert Opin. Biol. Ther.201818445946810.1080/14712598.2018.144522329482382
     [Google Scholar]
  44. SinclairR. Thirthar PalaniveluV. Tildrakizumab for the treatment of psoriasis.Expert Rev. Clin. Immunol.201915151210.1080/1744666X.2019.154449330394141
     [Google Scholar]
  45. GuC. YangJ. Risankizumab for the treatment of psoriasis.Expert Rev. Clin. Pharmacol.201912985185710.1080/17512433.2019.165782931460804
     [Google Scholar]
  46. Berth-JonesJ. The use of ciclosporin in psoriasis.J. Dermatolog. Treat.2005165-625827710.1080/0954663050042391416428145
     [Google Scholar]
  47. WozelG. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.Clin. Dermatol.200826544845910.1016/j.clindermatol.2007.10.02618755363
     [Google Scholar]
  48. VincentN. DR.D. BnV.H. Progress in psoriasis therapy via novel drug delivery systems.Dermatol. Rep.201461545110.4081/dr.2014.545125386329
     [Google Scholar]
  49. YadavK. SoniA. SinghD. SinghM.R. Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies.Prog. Biomater.202110111710.1007/s40204‑021‑00154‑733738750
     [Google Scholar]
  50. SindrilaruA. FilipA. Scharffetter-KochanekK. CrisanD. How can nanoparticle‐based technologies revolutionize the topical therapy in psoriasis?Exp. Dermatol.202029111097110310.1111/exd.1414932657487
     [Google Scholar]
  51. DinF. AmanW. UllahI. QureshiO.S. MustaphaO. ShafiqueS. ZebA. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.Int. J. Nanomedicine2017127291730910.2147/IJN.S146315
     [Google Scholar]
  52. RahmanM. AkhterS. AhmadJ. AhmadM.Z. BegS. AhmadF.J. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.Expert Opin. Drug Deliv.201512463565210.1517/17425247.2015.98208825439967
     [Google Scholar]
  53. SbidianE. ChaimaniA. Garcia-DovalI. DoneyL. DresslerC. HuaC. HughesC. NaldiL. AfachS. Le CleachL. NaldiL. Garcia-DovalI. Le CleachL. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Libr.202011CD01153510.1002/14651858.CD011535.pub331917873
     [Google Scholar]
  54. The Best New Medications & Treatments for Psoriasis.Available from: https://www.webmd.com/skin-problems-and-treatments/psoriasis/research (accessed October 27, 2021).
  55. JindalS. AwasthiR. SinghareD. KulkarniG.T. Topical delivery of tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis.Med. Hypotheses202014210983810.1016/j.mehy.2020.10983832442677
     [Google Scholar]
  56. SrisukP. ThongnopnuaP. RaktanonchaiU. KanokpanontS. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment.Int. J. Pharm.2012427242643410.1016/j.ijpharm.2012.01.04522310459
     [Google Scholar]
  57. DoppalapudiS. JainA. ChopraD.K. KhanW. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.Eur. J. Pharm. Sci.20179651552910.1016/j.ejps.2016.10.02527777066
     [Google Scholar]
  58. KimJ.K. ZebA. QureshiO.S. KimH-S. ChaJ-H. KimH.S. Improved skin permeation of methotrexate via nanosized ultradeformable liposomes.Int. J. Nanomedicine2016113813382410.2147/IJN.S10956527540293
     [Google Scholar]
  59. PandeyS.S. ShahK.M. MaulviF.A. DesaiD.T. GuptaA.R. JoshiS.V. ShahD.O. Topical delivery of cyclosporine loaded tailored niosomal nanocarriers for improved skin penetration and deposition in psoriasis: Optimization, ex vivo and animal studies.J. Drug Deliv. Sci. Technol.20216310244110.1016/j.jddst.2021.102441
     [Google Scholar]
  60. BahramizadehM. BahramizadehM. KiafarB. JafarianA.H. NikpoorA.R. HatamipourM. EsmailyH. RezaeemehrZ. GolmohammadzadehS. MoosavianS.A. JafariM.R. Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model.Int. J. Pharm.201956911862310.1016/j.ijpharm.2019.11862331419462
     [Google Scholar]
  61. FerreiraM. BarreirosL. SegundoM.A. TorresT. SeloresM. Costa LimaS.A. ReisS. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management.Colloids Surf. B Biointerfaces2017159232910.1016/j.colsurfb.2017.07.08028779637
     [Google Scholar]
  62. PradhanM. YadavK. SinghD. SinghM.R. Topical delivery of fluocinolone acetonide integrated NLCs and salicylic acid enriched gel: A potential and synergistic approach in the management of psoriasis.J. Drug Deliv. Sci. Technol.20216110228210.1016/j.jddst.2020.102282
     [Google Scholar]
  63. SharmaA. UpadhyayD.K. SarmaG.S. KaurN. GuptaG.D. NarangR.K. RaiV.K. Squalene integrated NLC based gel of tamoxifen citrate for efficient treatment of psoriasis: A preclinical investigation.J. Drug Deliv. Sci. Technol.20205610156810.1016/j.jddst.2020.101568
     [Google Scholar]
  64. PradhanM. SinghD. SinghM.R. Fabrication, optimization and characterization of Triamcinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis: Application of Box Behnken design, in vitro and ex vivo studies.J. Drug Deliv. Sci. Technol.20174132533310.1016/j.jddst.2017.07.024
     [Google Scholar]
  65. WangY. WangC. FuS. LiuQ. DouD. LvH. FanM. GuoG. LuoF. QianZ. Preparation of tacrolimus loaded micelles based on poly(ɛ-caprolactone)–poly(ethylene glycol)–poly(ɛ-caprolactone).Int. J. Pharm.20114071-218418910.1016/j.ijpharm.2011.01.01821251958
     [Google Scholar]
  66. PoupotM. GriffeL. MarchandP. MaravalA. RollandO. MartinetL. L’Faqihi-OliveF.E. TurrinC.O. CaminadeA.M. FourniéJ.J. MajoralJ.P. PoupotR. Design of phosphorylated dendritic architectures to promote human monocyte activation.FASEB J.200620132339235110.1096/fj.06‑5742com17077311
     [Google Scholar]
  67. Regina EbaniP. StefanelloL. Luiza KuhnB. Piccinin FrizzoC. Augusto Lima BurgoT. Luisa KlosterC. Antonio VillettiM. Carboxymethyl chitosan/ionic liquid imidazolium-based nanoparticles as nanocarriers for zinc phthalocyanine and its photodynamic activity.J. Mol. Liq.202133611687410.1016/j.molliq.2021.116874
     [Google Scholar]
  68. ElgewellyM.A. ElmasryS.M. SayedN.S.E. AbbasH. Resveratrol-loaded vesicular elastic nanocarriers gel in imiquimod-induced psoriasis treatment: In vitro and In vivo evaluation.J Pharm Sci2021111241743110.1016/j.xphs.2021.08.023
     [Google Scholar]
  69. AbbasN. HussainA. HafizM.A. KausarP. Formulation and evaluation of fluconazole loaded nanospongies for improved topical drug delivery.Brit.J. Pharm.20182210.5920/bjpharm.2017.29
     [Google Scholar]
  70. MahmoodS. MeiT.S. YeeW.X. HillesA.R. AlelwaniW. BannunahA.M. Synthesis of capsaicin loaded silver nanoparticles using green approach and its anti-bacterial activity against human pathogens.J. Biomed. Nanotechnol.20211781612162610.1166/jbn.2021.312234544538
     [Google Scholar]
  71. BessarH. VendittiI. BenassiL. VaschieriC. AzzoniP. PellacaniG. MagnoniC. BottiE. CasagrandeV. FedericiM. CostanzoA. FontanaL. TestaG. MostafaF.F. IbrahimS.A. RussoM.V. FratoddiI. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis.Colloids Surf. B Biointerfaces201614114114710.1016/j.colsurfb.2016.01.02126852097
     [Google Scholar]
  72. ChellaN. ShastriN.R. ChellaN. ShastriÁ.N.R. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.Mol. Pharmaceutics20171151651166610.1007/978‑981‑10‑3647‑7_8
     [Google Scholar]
  73. DaraeeH. EtemadiA. KouhiM. AlimirzaluS. AkbarzadehA. Application of liposomes in medicine and drug delivery.Artif Cells Nanomed. Biotechnol.201444138139110.3109/21691401.2014.953633
     [Google Scholar]
  74. BozzutoG. MolinariA. Liposomes as nanomedical devices.Int. J. Nanomedicine20151097599910.2147/IJN.S6886125678787
     [Google Scholar]
  75. Phospholipids | Introduction to Chemistry.Available from: https://courses.lumenlearning.com/introchem/chapter/phospholipids/ (accessed November 1, 2021).
  76. AlbertsB. JohnsonA. LewisJ. RaffM. RobertsK. WalterP. The Lipid BilayerNew YorkGarland Science2002Available from : https://www.ncbi.nlm.nih.gov/books/NBK26871/
    [Google Scholar]
  77. AkbarzadehA. Rezaei-SadabadyR. DavaranS. JooS.W. ZarghamiN. HanifehpourY. SamieiM. KouhiM. Nejati-KoshkiK. Liposome: classification, preparation, and applications.Nanoscale Res. Lett.20138110210.1186/1556‑276X‑8‑10223432972
     [Google Scholar]
  78. SercombeL. VeeratiT. MoheimaniF. WuS.Y. SoodA.K. HuaS. Advances and challenges of liposome assisted drug delivery.Front. Pharmacol.2015628610.3389/fphar.2015.0028626648870
     [Google Scholar]
  79. YadavD. SandeepK. PandeyD. DuttaR.K. Liposomes for drug delivery.J. Biotechnol. Biomater.2017741810.4172/2155‑952X.100027628778472
     [Google Scholar]
  80. XiL. LinZ. QiuF. ChenS. LiP. ChenX. WangZ. ZhengY. Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment.Acta Pharm. Sin. B202212133935210.1016/j.apsb.2021.07.01935127390
     [Google Scholar]
  81. LiuH. KangR.S. BagnowskiK. YuJ.M. RadeckiS. DanielW.L. AndersonB.R. NallagatlaS. SchookA. AgarwalR. GiljohannD.A. PallerA.S. Targeting the IL-17 Receptor using liposomal spherical nucleic acids as topical therapy for psoriasis.J. Invest. Dermatol.20201402435444.e410.1016/j.jid.2019.06.14631421125
     [Google Scholar]
  82. YadavK. SinghD. SinghM.R. PradhanM. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis.Med. Hypotheses202014511032210.1016/j.mehy.2020.11032233086162
     [Google Scholar]
  83. LuJ. GuoT. FanY. LiZ. HeZ. YinS. FengN. Recent developments in the principles, modification and application prospects of functionalized ethosomes for topical delivery.Curr. Drug Deliv.202118557058210.2174/156720181766620082609310232851961
     [Google Scholar]
  84. GuoT. LuJ. FanY. ZhangY. YinS. ShaX. FengN. TPGS assists the percutaneous administration of curcumin and glycyrrhetinic acid coloaded functionalized ethosomes for the synergistic treatment of psoriasis.Int. J. Pharm.202160412076210.1016/j.ijpharm.2021.12076234082000
     [Google Scholar]
  85. Pleguezuelos-VillaM. Diez-SalesO. MancaM.L. ManconiM. SauriA.R. Escribano-FerrerE. NácherA. Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis.Int. J. Pharm.202057311884410.1016/j.ijpharm.2019.11884431751638
     [Google Scholar]
  86. ZhangY. XiaQ. LiY. HeZ. LiZ. GuoT. WuZ. FengN. CD44 Assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: A new strategy for clustering drug in inflammatory skin.Theranostics201991486410.7150/thno.2971530662553
     [Google Scholar]
  87. ChandraA. AggarwalG. ManchandaS. NarulaA. Development of topical gel of methotrexate incorporated ethosomes and salicylic acid for the treatment of psoriasis.Pharm. Nanotechnol.20197536237410.2174/221173850766619090612364331490769
     [Google Scholar]
  88. NegiP. SharmaI. HemrajaniC. RathoreC. BishtA. RazaK. KatareO.P. Thymoquinone-loaded lipid vesicles: A promising nanomedicine for psoriasis.BMC Complement. Altern. Med.201919133410.1186/s12906‑019‑2675‑531771651
     [Google Scholar]
  89. KuotsuK. KarimK.M. MandalA.S. BiswasN. GuhaA. ChatterjeeS. BeheraM. Niosome: A future of targeted drug delivery systems.J. Adv. Pharm. Technol. Res.20101437438010.4103/0110‑5558.7643522247876
     [Google Scholar]
  90. Scioli MontotoS. MuracaG. RuizM.E. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects.Front. Mol. Biosci.2020758799710.3389/fmolb.2020.58799733195435
     [Google Scholar]
  91. RapalliV.K. SharmaS. RoyA. AlexanderA. SinghviG. Solid lipid nanocarriers embedded hydrogel for topical delivery of apremilast: In-vitro, ex-vivo, dermatopharmacokinetic and anti-psoriatic evaluation.J. Drug Deliv. Sci. Technol.20216310244210.1016/j.jddst.2021.102442
     [Google Scholar]
  92. DolatabadiS. KarimiM. NasirizadehS. HatamipourM. GolmohammadzadehS. JaafariM.R. Preparation, characterization and in vivo pharmacokinetic evaluation of curcuminoids-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs).J. Drug Deliv. Sci. Technol.20216210235210.1016/j.jddst.2021.102352
     [Google Scholar]
  93. DaraT. VatanaraA. Nabi MeybodiM. VakilinezhadM.A. MalvajerdS.S. VakhshitehF. ShamsianA. SharifzadehM. KaghazianH. MosaddeghM.H. Erythropoietin-loaded solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation.Colloids Surf. B Biointerfaces201917830731610.1016/j.colsurfb.2019.01.02730878805
     [Google Scholar]
  94. EssaghraouiA. BelfkiraA. HamdaouiB. NunesC. LimaS.A.C. ReisS. improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles.Nanomaterials201999120410.3390/nano909120431461853
     [Google Scholar]
  95. ChauhanI. YasirM. VermaM. SinghA.P. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery.Adv. Pharm. Bull.202010215016510.34172/apb.2020.02132373485
     [Google Scholar]
  96. PradhanM. AlexanderA. SinghM.R. SinghD. SarafS. SarafS. YadavK. Ajazuddin, Statistically optimized calcipotriol fused nanostructured lipid carriers for effectual topical treatment of psoriasis.J. Drug Deliv. Sci. Technol.20216110216810.1016/j.jddst.2020.102168
     [Google Scholar]
  97. AbasianP. GhanavatiS. RahebiS. Nouri KhorasaniS. KhaliliS. Polymeric nanocarriers in targeted drug delivery systems: A review.Polym. Adv. Technol.202031122939295410.1002/pat.5031
     [Google Scholar]
  98. Polymeric Micelle an overview | ScienceDirect Topics.Available from: https://www.sciencedirect.com/topics/engineering/polymeric-micelle
  99. JinY. ZhangX. ZhangB. KangH. DuL. LiM. Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis.Colloids Surf. B Biointerfaces201512840540910.1016/j.colsurfb.2015.02.03825766924
     [Google Scholar]
  100. SupasenaW. MuangnoiC. ThaweesestW. SongkramC. UedaK. HigashiK. MoribeK. TanasupawatS. RojsitthisakP. Enhanced antipsoriatic activity of mycophenolic acid against the tnf-α-induced hacat cell proliferation by conjugated poloxamer micelles.J. Pharm. Sci.202010921153116010.1016/j.xphs.2019.11.01031751564
     [Google Scholar]
  101. KhuranaB. AroraD. NarangR.K. QbD based exploration of resveratrol loaded polymeric micelles based carbomer gel for topical treatment of plaque psoriasis: In vitro, ex vivo and in vivo studies.J. Drug Deliv. Sci. Technol.20205910190110.1016/j.jddst.2020.101901
     [Google Scholar]
  102. BhattacharyaS. KuwarU.C. Dendrimer evolution timeline: Ground-breaking progress in cancer treatment.Ind. J. Pharm. Pharmacol.20218317918110.18231/j.ijpp.2021.030
     [Google Scholar]
  103. TripathiP.K. GorainB. ChoudhuryH. SrivastavaA. KesharwaniP. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment.Heliyon201953e0134310.1016/j.heliyon.2019.e0134330957038
     [Google Scholar]
  104. BhatM. PukaleS. SinghS. MittalA. ChitkaraD. Nano-enabled topical delivery of anti-psoriatic small molecules.J. Drug Deliv. Sci. Technol.20216210232810.1016/j.jddst.2021.102328
     [Google Scholar]
  105. ZielińskaA. CarreiróF. OliveiraA.M. NevesA. PiresB. VenkateshD.N. DurazzoA. LucariniM. EderP. SilvaA.M. SantiniA. SoutoE.B. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology.Molecules20202516373110.3390/molecules2516373132824172
     [Google Scholar]
  106. FereigS.A. El-ZaafaranyG.M. ArafaM.G. Abdel-MottalebM.M.A. Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis.Carbohydr. Polym.202126811823810.1016/j.carbpol.2021.11823834127220
     [Google Scholar]
  107. FereigS.A. El-ZaafaranyG.M. ArafaM.G. Abdel-MottalebM.M.A. Self-assembled tacrolimus-loaded lecithin-chitosan hybrid nanoparticles for in vivo management of psoriasis.Int. J. Pharm.202160812111410.1016/j.ijpharm.2021.12111434543618
     [Google Scholar]
  108. Sharadha M, GowdaD.V. Vishal GuptaN. AkhilaA.R. An overview on topical drug delivery system : Updated review.Int. J. Res. Pharmac. Sci.202011136838510.26452/ijrps.v11i1.1831
     [Google Scholar]
  109. CalóE. KhutoryanskiyV.V. Biomedical applications of hydrogels: A review of patents and commercial products.Eur. Polym. J.20156525226710.1016/j.eurpolymj.2014.11.024
     [Google Scholar]
  110. WichterleO. LímD. Hydrophilic gels for biological use.Nature1960185470611711810.1038/185117a0
     [Google Scholar]
  111. AhmedE.M. Hydrogel: Preparation, characterization, and applications: A review.J. Adv. Res.20156210512110.1016/j.jare.2013.07.00625750745
     [Google Scholar]
  112. LiQ. LiF. QiX. WeiF. ChenH. WangT. RETRACTED: Pluronic® F127 stabilized reduced graphene oxide hydrogel for the treatment of psoriasis: In vitro and in vivo studies.Colloids Surf. B Biointerfaces202019511124610.1016/j.colsurfb.2020.11124632659651
     [Google Scholar]
  113. RenuI. Renu KaivalyaI. PrasadD. SudhakarM. BhanjaS.B. TejaswiM. A review on nanosponges: an idiosyncratic approach for delivery of proactive molecules.Current Nanomaterials202393193208
     [Google Scholar]
  114. KumarS. PrasadM. RaoR. Topical delivery of clobetasol propionate loaded nanosponge hydrogel for effective treatment of psoriasis: Formulation, physicochemical characterization, antipsoriatic potential and biochemical estimation.Mater. Sci. Eng. C202111911160510.1016/j.msec.2020.11160533321649
     [Google Scholar]
  115. SardoiwalaM.N. KaundalB. ChoudhuryS.R. Development of engineered nanoparticles expediting diagnostic and therapeutic applications across blood–brain barrier.Handbook of Nanomaterials for Industrial ApplicationsElsevier201869670910.1016/B978‑0‑12‑813351‑4.00038‑9
     [Google Scholar]
  116. Calderón-JiménezB. JohnsonM.E. Montoro BustosA.R. MurphyK.E. WinchesterM.R. Vega BaudritJ.R. Silver nanoparticles: Technological advances, societal impacts, and metrological challenges.Front Chem.20175610.3389/fchem.2017.0000628271059
     [Google Scholar]
  117. DavidL. MoldovanB. VulcuA. OlenicL. Perde-SchreplerM. Fischer-FodorE. FloreaA. CrisanM. ChioreanI. ClichiciS. FilipG.A. Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract.Colloids Surf. B Biointerfaces201412276777710.1016/j.colsurfb.2014.08.01825174985
     [Google Scholar]
  118. NafisiS. MaibachH.I. Nanotechnology in Cosmetics.Cosmetic Science and TechnologyElsevier201733736910.1016/B978‑0‑12‑802005‑0.00022‑7
     [Google Scholar]
  119. Importance of patents in pharmaceutical industry.Available from: http://www.pharmabiz.com/ArticleDetails.aspx?aid=92383&sid=21
  120. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analoguesPatent US-2003171429A12003Available from: https://pubchem.ncbi.nlm.nih.gov/patent/US-2003171429-A1
  121. Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides.US7947283B22008
  122. AhmadM.Z. MohammedA.A. AlgahtaniM.S. MishraA. AhmadJ. Nanoscale topical pharmacotherapy in management of psoriasis: Contemporary research and scope.J. Funct. Biomater.20221411910.3390/jfb1401001936662067
     [Google Scholar]
  123. CassanoN. LoconsoleF. MiracapilloA. TravagliniM. DigiuseppeM.D. CongedoM. GalluccioA. BuquicchioR. MastrandreaV. FilieriM. RahoG. PezzaM. VenaG.A. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.Int. J. Immunopathol. Pharmacol.201023379780210.1177/03946320100230031420943050
     [Google Scholar]
  124. BanerjeeS. Use of TNF-alpha inhibitor for treatment of psoriasis.J. Dermatolog. Treat.201480816673
     [Google Scholar]
  125. DOWG.J. STEWARTD.M. Use of a clobetasol spray formulation to treat psoriasis.EP 1885373B1Available from: https://data.epo.org/gpi/EP1885373B1 2015
  126. SHRAIBOMN. Molecular and herbal combinations for treating psoriasis.US9095606B1Available from: https://patents.google.com/patent/US9095606B1/en 2015
  127. Crude dunaliella powder for use in treating psoriasis.2010Available from: http://clinicaltrials.gov/show/NCT0112 (accessed November 12, 2021).
  128. PuggioniF. Alves-CorreiaM. MohamedM.F. StomeoN. MagerR. MarinoniM. RaccaF. PaolettiG. VarricchiG. GiorgisV. MelioliG. CanonicaG.W. HefflerE. Immunostimulants in respiratory diseases: focus on Pidotimod.Multidiscip. Respir. Med.20191413110.1186/s40248‑019‑0195‑231700623
     [Google Scholar]
  129. LønnbergA.S. SkovL. ZachariaeC. Targeting of interleukin-17 in the treatment of psoriasis.Clin. Cosmet. Investig. Dermatol.2014725125910.2147/CCID.S6753425246805
     [Google Scholar]
  130. FPO IP Research & Communitiee.Available from: https://www.freepatentsonline.com/
  131. PatelP. PatelH. MehtaT. PanchalS. Formulation strategies for drug delivery of tacrolimus: An overview.Int. J. Pharm. Investig.20122416917510.4103/2230‑973X.10698123580932
     [Google Scholar]
  132. GoyalR. MacriL. K. KaplanH. M. KohnJ. Nanoparticles and nanofibers for topical drug delivery.J. Control Release2016240779210.1016/j.jconrel.2015.10.049
     [Google Scholar]
  133. Mohd NordinU.U. AhmadN. SalimN. Mohd YusofN.S. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.RSC Adv.20211146290802910110.1039/D1RA06087B35478537
     [Google Scholar]
  134. Metadichol® liquid and gel nanoparticle formulations.US9006292B2Available from: https://patents.google.com/patent/US9006292B2/en
  135. BabootaS. ShakeelF. AhujaA. AliJ. ShafiqS. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.Acta Pharm.200757331533210.2478/v10007‑007‑0025‑517878111
     [Google Scholar]
  136. ShakeelF. FaisalM.S. Nanoemulsion: A promising tool for solubility and dissolution enhancement of celecoxib.Pharm. Dev. Technol.2010151535610.3109/1083745090296795419552546
     [Google Scholar]
  137. CampanatiA. MaraniA. MartinaE. DiotalleviF. RadiG. OffidaniA. Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches.Biomedicines2021911151110.3390/biomedicines911151134829740
     [Google Scholar]
  138. WangC.Y. WangC.W. ChenC.B. ChenW.T. ChangY.C. HuiR.C.Y. ChungW.H. Pharmacogenomics on the treatment response in patients with psoriasis: An updated review.Int. J. Mol. Sci.2023248732910.3390/ijms2408732937108492
     [Google Scholar]
  139. JainA. JainP. SoniP. TiwariA. TiwariS.P. Design and characterization of silver nanoparticles of different species of curcuma in the treatment of cancer using human colon cancer cell line (HT-29).J. Gastrointest. Cancer2023541909510.1007/s12029‑021‑00788‑735043370
     [Google Scholar]
  140. SinghR PrasadJ SatapathyT JainP SinghS Pharmacological evaluation for anti-bacterial and anti-inflammatory potential of polymeric microparticles.Ind. J. Biochem. Biophys.202158156161
     [Google Scholar]
  141. IslamM. HuangY. JainP. FanB. TongL. WangF. Enzymatic hydrolysis of soy protein to high moisture textured meat analogue with emphasis on antioxidant effects: As a tool to improve techno-functional property.Biocatal. Agric. Biotechnol.20235010270010.1016/j.bcab.2023.102700
     [Google Scholar]
  142. PatelR. KuwarU. DhoteN. AlexanderA. NakhateK. JainP. Ajazuddin, Natural polymers as a carrier for the effective delivery of antineoplastic drugs.Curr. Drug Deliv.202421219321010.2174/156720182066623011217003536644864
     [Google Scholar]
  143. BhairamM. PrasadJ. VermaK. JainP. GidwaniB. Formulation of transdermal patch of Losartan Potassium & Glipizide for the treatment of hypertension & diabetes.Mater. Today Proc.202383596810.1016/j.matpr.2023.01.147
     [Google Scholar]
  144. PrasadJ. NetamA.K. SatapathyT. Prakash RaoS. JainP. Anti-hyperlipidemic and antioxidant activities of a combination of terminalia arjuna and commiphora mukul on experimental animals BT : Advances in biomedical engineering and technology. RizvanovA.A. SinghB.K. GanasalaP. SingaporeSpringer Singapore2021175188
     [Google Scholar]
  145. Sudhir DhoteN. Dineshbhai PatelR. KuwarU. AgrawalM. AlexanderA. JainP. Application of thermoresponsive smart polymers based in situ gel as a novel carrier for tumor targeting.Curr. Cancer Drug Targets20242024122
     [Google Scholar]
  146. NetamA.K. PrasadJ. SatapathyT. JainP. Evaluation for toxicity and improved therapeutic effectiveness of natural polymer co-administered along with venocin in acetic acid-induced colitis using rat model BT : Advances in biomedical engineering and technology. RizvanovA.A. SinghB.K. GanasalaP. SingaporeSpringer Singapore2021207220
     [Google Scholar]
  147. ChengX. XieQ. SunY. Advances in nanomaterial-based targeted drug delivery systems.Front. Bioeng. Biotechnol.202311117715110.3389/fbioe.2023.117715137122851
     [Google Scholar]
  148. ThirumalD. SindhuR.K. GoyalS. SehgalA. KumarA. BabuM.A. KumarP. Pathology and treatment of psoriasis using nanoformulations.Biomedicines2023116158910.3390/biomedicines1106158937371684
     [Google Scholar]
  149. YetisginA.A. CetinelS. ZuvinM. KosarA. KutluO. Therapeutic nanoparticles and their targeted delivery applications.Molecules2020259219310.3390/molecules2509219332397080
     [Google Scholar]
  150. SoaresS. SousaJ. PaisA. VitorinoC. Nanomedicine: Principles, properties, and regulatory issues.Front Chem.2018636010.3389/fchem.2018.0036030177965
     [Google Scholar]
  151. AdnanM. AkhterM.H. AfzalO. AltamimiA.S.A. AhmadI. AlossaimiM.A. JaremkoM. EmwasA.H. HaiderT. HaiderM.F. Exploring nanocarriers as treatment modalities for skin cancer.Molecules20232815590510.3390/molecules2815590537570875
     [Google Scholar]
/content/journals/cnano/10.2174/0115734137301584240722054651
Loading
Novel Approaches and Applications of Nanotechnology in the Delivery of Topical Drugs for Psoriasis via Nanocarriers
Curr. Nanosci. 21, 658 (2025); https://doi.org/10.2174/0115734137301584240722054651
/content/journals/cnano/10.2174/0115734137301584240722054651
/content/journals/cnano/10.2174/0115734137301584240722054651
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): drug; drug delivery; nanocarriers; Psoriasis; skin; topical formulation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test